S'abonner

Genomic evidence for reinfection with SARS-CoV-2: a case study - 24/12/20

Doi : 10.1016/S1473-3099(20)30764-7 
Richard L Tillett, PhD a, b, Joel R Sevinsky, PhD c, Paul D Hartley, PhD d, Heather Kerwin, MPH e, Natalie Crawford, MD f, Andrew Gorzalski, PhD g, Chris Laverdure, BS g, Subhash C Verma, PhD h, Cyprian C Rossetto, PhD h, David Jackson, MSc j, Megan J Farrell, BS j, Stephanie Van Hooser, MBA MLS(ASCP) g, Mark Pandori, PhD g, i,
a Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas, NV, USA 
b University of Nevada, Reno Center for Bioinformatics, Reno, NV, USA 
c Theiagen Consulting LLC, Highlands Ranch, CO, USA 
d Nevada Genomics Center, University of Nevada, Reno, NV, USA 
e Division of Epidemiology & Public Health Preparedness, Washoe County Health District, Reno, NV, USA 
f Renown Health, Reno, NV, USA 
g Nevada State Public Health Laboratory, Reno, NV, USA 
h Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, NV, USA 
i Department of Pathology and Laboratory Medicine, University of Nevada, Reno School of Medicine, Reno, NV, USA 
j Forensic Science Division, Washoe County Sheriff’s Office, Reno, NV, USA 

* Correspondence to: Dr Mark Pandori, Department of Pathology and Laboratory Medicine, University of Nevada, Reno School of Medicine, Reno, NV 89557, USA Department of Pathology and Laboratory Medicine University of Nevada Reno School of Medicine Reno NV 89557 USA

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

Background

The degree of protective immunity conferred by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently unknown. As such, the possibility of reinfection with SARS-CoV-2 is not well understood. We describe an investigation of two instances of SARS-CoV-2 infection in the same individual.

Methods

A 25-year-old man who was a resident of Washoe County in the US state of Nevada presented to health authorities on two occasions with symptoms of viral infection, once at a community testing event in April, 2020, and a second time to primary care then hospital at the end of May and beginning of June, 2020. Nasopharyngeal swabs were obtained from the patient at each presentation and twice during follow-up. Nucleic acid amplification testing was done to confirm SARS-CoV-2 infection. We did next-generation sequencing of SARS-CoV-2 extracted from nasopharyngeal swabs. Sequence data were assessed by two different bioinformatic methodologies. A short tandem repeat marker was used for fragment analysis to confirm that samples from both infections came from the same individual.

Findings

The patient had two positive tests for SARS-CoV-2, the first on April 18, 2020, and the second on June 5, 2020, separated by two negative tests done during follow-up in May, 2020. Genomic analysis of SARS-CoV-2 showed genetically significant differences between each variant associated with each instance of infection. The second infection was symptomatically more severe than the first.

Interpretation

Genetic discordance of the two SARS-CoV-2 specimens was greater than could be accounted for by short-term in vivo evolution. These findings suggest that the patient was infected by SARS-CoV-2 on two separate occasions by a genetically distinct virus. Thus, previous exposure to SARS-CoV-2 might not guarantee total immunity in all cases. All individuals, whether previously diagnosed with COVID-19 or not, should take identical precautions to avoid infection with SARS-CoV-2. The implications of reinfections could be relevant for vaccine development and application.

Funding

Nevada IDEA Network of Biomedical Research, and the National Institute of General Medical Sciences (National Institutes of Health).

Le texte complet de cet article est disponible en PDF.

Plan


© 2020  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 21 - N° 1

P. 52-58 - janvier 2021 Retour au numéro
Article précédent Article précédent
  • Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
  • Shengli Xia, Yuntao Zhang, Yanxia Wang, Hui Wang, Yunkai Yang, George Fu Gao, Wenjie Tan, Guizhen Wu, Miao Xu, Zhiyong Lou, Weijin Huang, Wenbo Xu, Baoying Huang, Huijuan Wang, Wei Wang, Wei Zhang, Na Li, Zhiqiang Xie, Ling Ding, Wangyang You, Yuxiu Zhao, Xuqin Yang, Yang Liu, Qian Wang, Lili Huang, Yongli Yang, Guangxue Xu, Bojian Luo, Wenling Wang, Peipei Liu, Wanshen Guo, Xiaoming Yang
| Article suivant Article suivant
  • Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis
  • Daniel J Weiss, Amelia Bertozzi-Villa, Susan F Rumisha, Punam Amratia, Rohan Arambepola, Katherine E Battle, Ewan Cameron, Elisabeth Chestnutt, Harry S Gibson, Joseph Harris, Suzanne Keddie, Justin J Millar, Jennifer Rozier, Tasmin L Symons, Camilo Vargas-Ruiz, Simon I Hay, David L Smith, Pedro L Alonso, Abdisalan M Noor, Samir Bhatt, Peter W Gething

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.